Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR421869 long-term follow-up in Usher syndrome Type 1B
NCT02065011Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2013
- Primary completion
- Jun 2031
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of SAR421869 in Usher syndrome type 1B (USH1B), sponsored by Sanofi. Started Sep 2013; status: active, not recruiting.
02
Drugs
SAR421869
03
Conditions
Usher syndrome type 1B (USH1B)
Beyond the preview
Go deeper on NCT02065011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065011.